OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 32 BIOGEN 2021 YEAR IN REVIEW Advancing responsible product development Biogen is advancing responsible product development and addressing the interest of our stakeholders in material environmental, social and governance (ESG) issues. This begins in the earliest stages of R&D, with clear guidelines around issues such as bioethics and the use of animals in research. In forging and refining our approach to these and other issues, we review industry standards and best practices and consult with stakeholder groups. We also transparently disclose our policies, principles and positions on these and other issues, available here : – Animal Welfare – Clinical Research and Bioethics – Clinical Trial Transparency and Data Sharing – Product Stewardship – Research Collaborations – Stem Cells Responsible and sustainable pharmaceutical operations and technology We take seriously our responsibility to create, safeguard and supply quality medicine, which guides every aspect of our manufacturing operations. We successfully manufacture large molecule therapies and small molecule therapies, and we have an oral solid dose facility and 263,000 liters of bioreactor capacity – one of the largest among biotech companies worldwide – enabling us to manufacture and supply medicines to patients in more than 90 countries. SPOTLIGHT Breaking ground on our new gene therapy manufacturing facility In 2021, our Research Triangle Park (RTP) manufacturing campus in North Carolina and Biogen executives hosted Machelle Baker Sanders, a former Biogen employee and North Carolina Secretary of Commerce, for the groundbreaking of our new gene therapy manufacturing facility. The $200 million investment will expand existing operations across Biogen’s RTP campuses. This investment reflects our commitment to advancing our gene therapy portfolio across multiple therapeutic areas, complemented by differentiated, sustainable and advanced manufacturing capabilities to deliver a reliable supply of high-quality medicines to the patients we serve. The site will be 175,000 square feet and designed in compliance with the most advanced sustainability standards regarding energy use, waste management and water consumption. The facility is expected to be operational by 2023. “Building what will now be in RTP our seventh manufacturing plant across four different therapeutic modalities on a more than 250-acre campus, is not only a strategic investment in manufacturing and technology, but importantly an investment in future patients, their families and loved ones,” said Nicole Murphy, Head of Pharmaceutical Operations and Technology.